Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.
Proton-pump inhibitor
| Proton-pump inhibitor | |
|---|---|
| Drug class | |
 General structure of a proton-pump inhibitor | |
| Class identifiers | |
| Use | Reduction of gastric acid production |
| ATC code | A02BC |
| Mechanism of action | Enzyme inhibitor |
| Biological target | H+/K+ ATPase |
| Clinical data | |
| Drugs.com | Drug Classes |
| WebMD | MedicineNet |
| External links | |
| MeSH | D054328 |
| Legal status | |
| In Wikidata | |
Proton-pump inhibitors (PPIs) are a class of medications that cause a profound and prolonged reduction of stomach acid production. They do so by irreversibly inhibiting the stomach's H+/K+ ATPase proton pump.[1] The body eventually synthesizes new proton pumps to replace the irreversibly inhibited ones, a process driven by normal cellular turnover, which gradually restores acid production.[2]
Proton-pump inhibitors have largely superseded the H2-receptor antagonists, a group of medications with similar effects but a different mode of action, and heavy use of antacids.[3] A potassium-competitive acid blocker (PCAB) revaprazan was marketed in Korea as an alternative to a PPI. A newer PCAB vonoprazan with a faster and longer lasting action than revaprazan, and PPIs has been marketed in Japan (2013), Russia (2021), and the US (2023).[4][5][6]
PPIs are among the most widely sold medications in the world. The class of proton-pump inhibitor medications is on the World Health Organization's List of Essential Medicines.[7][8] Omeprazole is the specific listed example.[7][8]
- ^ Cite error: The named reference
TI(99)2016was invoked but never defined (see the help page). - ^ Fossmark R, Martinsen TC, Waldum H (21 October 2019). "Adverse Effects of Proton Pump Inhibitors-Evidence and Plausibility". International Journal of Molecular Sciences. 20 (20): 5203. doi:10.3390/ijms20205203. PMC 6829383. PMID 31640115.
- ^ Sandhu DS, Fass R (January 2018). "Current Trends in the Management of Gastroesophageal Reflux Disease". Gut Liver. 12 (1): 7–16. doi:10.5009/gnl16615. PMC 5753679. PMID 28427116.
- ^ Garnock-Jones KP (2015). "Vonoprazan: first global approval". Drugs. 75 (4): 439–43. doi:10.1007/s40265-015-0368-z. PMID 25744862. S2CID 43293048.
- ^ "Russian State Register of Medicines. Vocinti (vonoprazan) Film-Coated Tablets. Full Prescribing Information". grls.rosminzdrav.ru (in Russian). Takeda Pharmaceutical Company Limited. Archived from the original on 18 February 2023. Retrieved 18 February 2023.
- ^ "Phathom Pharmaceuticals Announces Commercial Availability of Voquezna (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn". GlobeNewswire (Press release). Phathom Pharmaceuticals. 28 November 2023. Retrieved 26 January 2024.
- ^ a b World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ a b World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
Previous Page Next Page
مثبط مضخة البروتون Arabic প্রোটন পাম্প ইনহিবিটর Bengali/Bangla Inhibidor de la bomba de protons Catalan Syrepumpehæmmer Danish Protonenpumpenhemmer German Inhibidores de la bomba de protones Spanish مهارکنندگان پمپ پروتونی FA PPI-lääkkeet Finnish Inhibiteur de la pompe à protons French Inhibidor da bomba de protóns GL
